LONDON: The UK Government has authorised the use of anti-inflammatory drug dexamethasone for the treatment of Covid-19 on the National Health Service (NHS), immediately after the report of positive data from the RECOVERY trial.

Preliminary data showed that the low-cost, commonly available drug reduced death by up to one third in hospitalised patients with severe respiratory complications caused by Covid-19.

The drug has been approved for the treatment of patients needing oxygen, including those on ventilators.

According to the trial results, dexamethasone decreased the risk of death by 35% in patients on ventilation and 20% in patients on oxygen, leading to a 17% reduction in the total 28-day mortality rate.

Originally Posted on Abbtak Tv

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.